A5045486705- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Protein Degradation and Inhibitors
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Galectins and Cancer Biology
- CNS Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hemoglobinopathies and Related Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Cancer Treatment and Pharmacology
Centre Hospitalier Universitaire de Montpellier
2021-2025
Institut de Génétique Humaine
2021-2025
Centre National de la Recherche Scientifique
2021-2025
Université de Montpellier
2021-2025
Dana-Farber Cancer Institute
2019-2025
Harvard University
2019-2025
Institut Universitaire de France
2025
Clinique du Millénaire
2023
Centre Hospitalier Universitaire de Lille
2014-2023
Institut Universitaire de Recherche Clinique
2023
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize chromosomal rearrangement individual leukemia patients. present data molecular characterization 1590 MLL-rearranged biopsy samples obtained from The precise localization genomic breakpoints within involved translocation partner genes (TPGs) were determined...
Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenström's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect adding to rituximab this disease, both those who had not received previous treatment and disease recurrence.We randomly assigned 150 symptomatic receive plus or placebo rituximab. The primary end point was progression-free survival, as assessed by an independent review committee. Key secondary points were response rates,...
Abstract Purpose: Whole-genome sequencing has revealed MYD88 L265P and CXCR4 mutations (CXCR4mut) as the most prevalent somatic in Waldenström macroglobulinemia. mutation proved to be of critical importance macroglobulinemia, part due its role a mechanism resistance several agents. We have therefore sought unravel different aspects Experimental Design: scanned two coding exons macroglobulinemia using deep next-generation Sanger 98 patients with correlated SNP array landscape mutational...
Abstract Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti‐PD‐1 not well known. We retrospectively investigated the salvage therapies for unsatisfactory therapy, assessed by PET‐CT according Lugano criteria, 30 R/R HL patients. Patients were...
PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. METHODS Patients had confirmed symptomatic WM, either previously untreated or treated; patients with prior rituximab at least a minor response to their last rituximab-based regimen. were randomly assigned once-daily ibrutinib 420 mg plus placebo (n = 75 per arm). primary...
CD19 chimeric antigen receptor (CAR) T cells can induce prolonged remissions and potentially cure a significant proportion of patients with relapsed/refractory large B-cell lymphomas. However, some may die causes unrelated to lymphoma after CAR T-cell therapy. To date, little is known about the nonrelapse mortality (NRM) Using French DESCAR-T registry, we analyzed incidence NRM identified risk factors NRM. We report on 957 who received standard-of-care axicabtagene ciloleucel (n = 598) or...
Purpose:TP53 is a tumor-suppressor gene that functions as regulator influencing cellular responses to DNA damage, and TP53 alterations are associated with pejorative outcome in most B-lymphoid disorders. Little known regarding alteration Waldenstrom's macroglobulinemia (WM).Experimental Design: Here, we have explored the incidence of using Sanger sequencing ultradeep-targeted 125 WM 10 immunoglobulin M (IgM) monoclonal gammopathy undetermined significance (MGUS), along clinical features...
Summary Bing‐Neel syndrome (BNS), a rare neurological associated with Waldenström macroglobulinaemia (WM), is direct involvement of the central nervous system by lymphoplasmacytoid cells characterized an adverse prognostic. The MYD88 L265P mutation has been identified in vast majority patients WM. diagnosis BNS often challenging because variety clinical presentations difficult histological techniques. We hypothesized that identification cerebrospinal fluid (CSF) would contribute to addition...
Solitary plasmacytoma (SP) is a localized proliferation of monoclonal plasma cells in either bone or soft tissue, without evidence multiple myeloma (MM), and whose prognosis marked by high risk transformation to MM.We studied the impact FDG-PET/CT (2[18F]fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography) on SP overt MM among other markers series 43 patients diagnosed with SP.Median age was 57.5 years; 48% had an abnormal involved serum-free light chain (sFLC) value,...
Gray-zone lymphoma (GZL) with features intermediate between classic Hodgkin (cHL) and large B-cell (LBCL) was introduced as a provisional entity into the World Health Organization classification in 2008. However, diagnostic criteria are imprecise, reliable identification of GZL cases remains challenging. Here, we describe histopathologic 139 from retrospective Lymphoma Study Association (LYSA) study goal to improve accuracy. Inclusion were based on literature review an expert consensus...
The histone-methyl transferase EZH2, catalytic subunit of the PRC2 complex involved in transcriptional regulation, is mutated approximately 25% germinal center B-cell lymphomas. Aberrant proliferative dependency on EZH2 activity can be targeted by orally available inhibitor tazemetostat (EPZ-6438). We report results phase Ib plus R-CHOP combination (NCT02889523), patients 60 to 80 years age with newly diagnosed diffuse large lymphoma.The primary objective this dose-escalation study was...
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, may enhance cytotoxic of rituximab. Here we report results patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular (FL), other lymphomas, phase 1 studies evaluating urelumab alone (NCT01471210) combined rituximab (NCT01775631). Sixty received (0.3 mg/kg IV Q3W, 8 mg Q6W); 46 (0.1 mg/kg, 0.3 Q3W)...
Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape pathways and deepen responses. This open-label, phase Ib, sequential dose-escalation dose-expansion study evaluated the safety, tolerability, pharmacokinetics, preliminary efficacy selective BTK inhibitor tirabrutinib alone, combination with PI3K delta (PI3Kδ) idelalisib, or spleen (SYK) entospletinib patients...
SNP array (SNPa) was developed to detect copy number alteration (CNA) and loss of heterozygosity (LOH) without changes, CN‐LOH. We aimed identify novel genomic aberrations using SNPa in 31 WM with paired samples. Methylation status mutation were analyzed on target genes. A total 61 genetic observed, 58 CNA (33 gains, 25 losses) 58% patients CN‐LOH 6% patients. The widely distributed throughout the genome, including 12 recurrent regions identified new cryptic clonal chromosomal lesions that...